Gout Therapeutic Market Is Likely To Engender Revenue Of US$ 3820 Mn By 2027

The global gout therapeutic market is driven by high prevalence and rapid increase in incidence of gout arthritis across the globe. The global gout therapeutics market was valued at US$ 1874 Mn in 2018 and is projected to reach US$ 3820 Mn by 2027, expanding at a CAGR of 8.3% from 2019 to 2027.

High growth rate of the gout therapeutics market is attributed because of following factors

• Increase in drug pipeline
• Easy availability,
• Rise in the demand for biologics for treatment of gout across the globe.

Gout is a type of inflammatory arthritis caused by small crystals of a chemical called uric acid that form in the joints. If uric acid levels in the blood remain elevated, thin rod-like crystals can form and deposit in the joints, which can lead to severe pain, tenderness, stiffness, swelling, and joint damage.

Gout has both active and inactive periods. Active periods of gout are known as ‘attacks’ and can vary in severity and length. Diagnosis of gout is confirmed by synovial fluid analysis. Incidence of gout has been rising consistently over the last few years.

• According to Nationwide Emergency Department Sample (NEDS), total number of ED visits per year among patients with a primary diagnosis of acute gout increased 26.8% between 2006 and 2014; from 168,580 to 213,780. 

Traditional therapies are witnessing a shift toward biologics. Rise in demand for effective treatment and new therapeutics launches are projected to propel the global gout therapeutics market during the forecast period. Efforts are being taken in various countries to spread awareness about chronic diseases and role of biologics in treating gout among the general population.

Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=66875

The global gout therapeutic market has been segmented based on drug type, distribution channel, and region. In terms of drug type, the gout therapeutics market has been classified into NSAIDS, colchicine, corticosteroids, antihyperuricemic agents (urate-lowering drugs), and biologics. The antihyperuricemic agents (urate-lowering drugs) segment dominated the gout therapeutics market in 2018.

The segment is projected to expand at a high CAGR from 2019 to 2027. Biologics have witnessed rapid adoption and are replacing NSAIDS and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics market share during the forecast period.

Antihyperuricemic agents (urate-lowering drugs) are usually prescribed as the first line of treatment. Moreover, adoption and success of Target-2-Treat (T2T) strategy using a combination of biologic and conventional synthetic urate-lowering drugs for the treatment of severe gout disease are key factors fueling biologic and antihyperuricemic agents segments.